Long-Term Follow-Up Data Confirm Sustained Survival Benefits of PD-1 Inhibitors in Nasopharyngeal and Esophageal Cancers
Key Insights
Extended follow-up from the RATIONALE-309 trial shows tislelizumab plus chemotherapy maintained progression-free survival benefits in recurrent or metastatic nasopharyngeal cancer patients after 3 years.
Six-year follow-up data from JUPITER-02 demonstrates toripalimab plus chemotherapy achieved median overall survival of 64.8 months versus 33.7 months with chemotherapy alone in nasopharyngeal carcinoma (search).
Final analysis of JUPITER-06 confirms toripalimab plus chemotherapy significantly improved overall survival to 17.7 months versus 12.9 months with placebo in advanced esophageal squamous cell carcinoma (search).
Two major clinical trials have provided compelling long-term evidence supporting the sustained efficacy of PD-1 (search) inhibitors combined with chemotherapy in treating nasopharyngeal carcinoma (search) and esophageal squamous cell carcinoma (search), with follow-up data extending up to six years demonstrating durable survival benefits.
Tislelizumab Maintains Long-Term Benefits in Nasopharyngeal Cancer
The 3-year follow-up analysis of the RATIONALE-309 trial, published in JAMA Oncology, confirmed that tislelizumab plus chemotherapy continues to provide sustained progression-free survival benefits in patients with recurrent or metastatic nasopharyngeal cancer. The double-blind multicenter trial enrolled 263 Asian patients, with 248 being Chinese, who were randomly assigned to receive either tislelizumab at 200 mg or placebo every 3 weeks, both combined with gemcitabine and cisplatin.
After a median follow-up of 27.5 months, the tislelizumab group demonstrated superior outcomes with median progression-free survival of 9.6 months compared to 7.4 months in the placebo group, representing a hazard ratio of 0.53. Overall survival showed a trend toward improvement, with median overall survival reaching 45.3 months in the tislelizumab group versus 31.8 months in the placebo group.
Notably, exploratory biomarker analysis revealed associations between overall survival benefit and activated immune signatures, including B cells, T cells, and activated dendritic cells, specifically in the tislelizumab group. Patients with high B-cell expression in the tislelizumab group showed particularly favorable outcomes with a hazard ratio for overall survival of 0.41.
Six-Year JUPITER-02 Data Shows Remarkable Survival Extension
Long-term follow-up data from the JUPITER-02 trial presented at the 2025 ESMO Asia Congress provided unprecedented six-year survival data for toripalimab in nasopharyngeal carcinoma (search). The international, multicenter, randomized, double-blind Phase III study enrolled 289 patients with primary metastatic or recurrent nasopharyngeal carcinoma who were treatment naïve for recurrent/metastatic disease.
After 68 months of follow-up, the results demonstrated a remarkable survival advantage, with median overall survival reaching 64.8 months in the toripalimab plus gemcitabine-cisplatin arm compared to 33.7 months with chemotherapy alone. This represents a 31.1-month improvement in median overall survival, with a stratified hazard ratio for death of 0.62.
A sensitivity analysis adjusting for post-progression anti-PD-L1 (search) therapy showed even more pronounced benefits, with median overall survival of 61.0 months in the toripalimab arm compared to 25.1 months in the placebo arm, yielding a hazard ratio of 0.52.
Toripalimab Confirms Efficacy in Esophageal Cancer
The final analysis of the JUPITER-06 trial provided definitive evidence for toripalimab's efficacy in advanced esophageal squamous cell carcinoma (search). This randomized, double-blind, placebo-controlled Phase III trial enrolled 514 previously untreated patients with advanced or metastatic esophageal squamous cell carcinoma across multiple sites in China.
After a median follow-up of 14.2 months, the final overall survival analysis showed significant improvement with toripalimab plus cisplatin-paclitaxel achieving median overall survival of 17.7 months versus 12.9 months with placebo plus chemotherapy, representing a hazard ratio of 0.72. The 3-year overall survival rates were 29.7% and 19.9%, respectively.
Biomarker Insights Guide Future Treatment Strategies
Comprehensive genomic analysis from the JUPITER-06 study identified several potential predictive biomarkers for long-term survival benefit. While total tumor mutation burden did not correlate with survival benefit, copy number alteration-corrected tumor mutation burden (ccTMB) showed promise as a predictive marker. Patients in the toripalimab arm with higher ccTMB demonstrated significantly improved 3-year overall survival rates of 43.6% versus 24.6% for those with lower ccTMB.
The established genome-based immuno-oncology classification (EGIC) scheme effectively identified long-term survivors, with EGIC1 classification patients showing median overall survival of 30.4 months on toripalimab plus chemotherapy compared to 11.2 months for placebo plus chemotherapy.
Safety Profile Remains Manageable
Both trials demonstrated acceptable safety profiles for PD-1 (search) inhibitor combinations. In RATIONALE-309, grade 3 or worse adverse events occurred in 85% of patients in both treatment arms, with immune-mediated adverse events occurring in 53.4% versus 37.7% of patients in the tislelizumab and placebo groups, respectively.
The JUPITER-06 final analysis confirmed no new safety signals with extended follow-up, with the most commonly reported adverse events including anemia, leukopenia, neutropenia, nausea, fatigue, and vomiting occurring at rates of 30% or higher.
These comprehensive long-term analyses establish PD-1 (search) inhibitors combined with chemotherapy as a new standard of care for both nasopharyngeal carcinoma (search) and esophageal squamous cell carcinoma (search), with biomarker-driven approaches potentially enabling more personalized treatment strategies in the future.